Avrobio (NASDAQ:AVRO) Stock Rating Reaffirmed by Cowen

Avrobio (NASDAQ:AVRO)‘s stock had its “buy” rating reissued by Cowen in a research note issued to investors on Monday, TipRanks reports.

A number of other analysts also recently issued reports on the stock. Zacks Investment Research upgraded shares of Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a report on Tuesday. Janney Montgomery Scott started coverage on shares of Amicus Therapeutics in a research note on Friday, April 5th. They issued a “buy” rating and a $13.91 target price for the company. Mizuho started coverage on shares of Avrobio in a research note on Wednesday, June 26th. They issued a “buy” rating and a $28.00 target price for the company. Finally, HC Wainwright set a $25.00 target price on shares of Onconova Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, May 14th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $27.90.

NASDAQ AVRO traded up $3.74 during trading hours on Monday, reaching $22.90. 5,567,606 shares of the company were exchanged, compared to its average volume of 186,748. Avrobio has a 1 year low of $11.85 and a 1 year high of $53.70. The firm has a 50 day simple moving average of $14.85. The company has a market cap of $396.49 million and a PE ratio of -6.33.

Avrobio (NASDAQ:AVRO) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.01). On average, research analysts forecast that Avrobio will post -2.93 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of AVRO. JPMorgan Chase & Co. increased its stake in shares of Avrobio by 90.8% in the first quarter. JPMorgan Chase & Co. now owns 1,224,455 shares of the company’s stock worth $26,999,000 after purchasing an additional 582,639 shares in the last quarter. BlackRock Inc. increased its stake in shares of Avrobio by 73.4% in the fourth quarter. BlackRock Inc. now owns 651,959 shares of the company’s stock worth $10,854,000 after purchasing an additional 276,018 shares in the last quarter. Emerald Advisers LLC increased its stake in shares of Avrobio by 61.4% in the first quarter. Emerald Advisers LLC now owns 614,408 shares of the company’s stock worth $13,548,000 after purchasing an additional 233,772 shares in the last quarter. Emerald Mutual Fund Advisers Trust increased its stake in shares of Avrobio by 40.2% in the first quarter. Emerald Mutual Fund Advisers Trust now owns 522,590 shares of the company’s stock worth $11,523,000 after purchasing an additional 149,725 shares in the last quarter. Finally, Victory Capital Management Inc. increased its stake in shares of Avrobio by 4,614.3% in the first quarter. Victory Capital Management Inc. now owns 136,761 shares of the company’s stock worth $3,016,000 after purchasing an additional 133,860 shares in the last quarter. Hedge funds and other institutional investors own 71.13% of the company’s stock.

About Avrobio

AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.

See Also: What causes a recession?

Analyst Recommendations for Avrobio (NASDAQ:AVRO)

Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.